Cargando…
Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
CCNE1 amplification is a recurrent alteration associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma (HGSC). We aimed to investigate whether immunohistochemistry (IHC) can be used to identify CCNE1 amplification status and to validate whether CCNE1 high‐level amplification...
Autores principales: | Chan, Angela MY, Enwere, Emeka, McIntyre, John B, Wilson, Holly, Nwaroh, Chidera, Wiebe, Nicholas, Ou, Young, Liu, Shuhong, Wiedemeyer, Katharina, Rambau, Peter F, Grevers, Xin, Morris, Donald G, Neri, Paola, Gilks, C Blake, Visser, Frank, Le, Nhu, Luo, Li, Cook, Linda S, Köbel, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578325/ https://www.ncbi.nlm.nih.gov/pubmed/32391646 http://dx.doi.org/10.1002/cjp2.168 |
Ejemplares similares
-
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022) -
CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017) -
A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
por: Communal, Laudine, et al.
Publicado: (2021) -
CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma
por: Margolis, Benjamin, et al.
Publicado: (2021) -
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)